Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ – GuruFocus.com

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ - GlobeNewswire May 19, 2022 Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ  GlobeNewswire
• Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on ... - The Bakersfield Californian May 19, 2022 Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on ...  The Bakersfield Californian
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• THE AMERICAN PARKINSON DISEASE ASSOCIATION (APDA) ANNOUNCES NEW LEADERSHIP FOR BOARD OF DIRECTORS March 10, 2021 THE AMERICAN PARKINSON DISEASE ASSOCIATION (APDA) ANNOUNCES NEW LEADERSHIP FOR BOARD OF DIRECTORS   NEW YORK, NY, March 11, 2021 – At its recent annual meeting, the American Parkinson Disease Association (APDA) announced the election of Thomas K. Penett, Esq. as Chairman of the National Board of Directors. Mr. Penett succeeds former APDA Chairman, Patrick McDermott. “We are pleased to welcome…
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board - Nasdaq March 25, 2019 Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board  NasdaqPLANO, Texas, March 25, 2019-- Nuvectra Corporation, a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl,.
• Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors - Northeast Mississippi Daily Journal September 9, 2021 Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors  Northeast Mississippi Daily Journal
• Meet the Newest Davis Phinney Foundation Leaders in Parkinson’s December 8, 2020 We are delighted to announce the creation of The Davis Phinney Foundation Inclusion, Diversity, Equity, and Access (IDEA) Advisory Board. This team of renowned healthcare providers and leaders in the fields of equity and inclusion will play an integral role in our work to better understand and change deeply rooted inequities in healthcare that black, brown, and indigenous communities; LGBTQ+;…
• Top Parkinson’s Experts Join Inhibikase Therapeutics Scientific Advisory Board March 11, 2019 To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB). The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline includes prospective therapies developed from its proprietary Re-engineering Approach with Metabolism Preserved…
• Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors - GlobeNewswire August 23, 2021 Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors  GlobeNewswire
• Denali’s Phase I results May 27, 2021 # # # # Leucine-rich repeat kinase 2 (or LRRK2) is a large, multi function protein that is associated with Parkinson’s. People with genetic variations in the region of DNA that provides the instructions for making LRRK2 protein have a higher risk of developing the condition. In many cases of Parkinson’s, LRRK2 can become hyperactive. Researchers and biotech companies have…
• Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson's Disease and Type 1 Diabetes Drugs - Marketscreener.com September 13, 2021 Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson's Disease and Type 1 Diabetes Drugs  Marketscreener.com
• Year in review: 2021 December 31, 2021 # # # # As with the preceding year, 2021 proved to be challenging due to the continuing COVID-19 pandemic (and it is not over yet). Vaccines were rolled out with remarkable speed, but equally new variants of the virus popped up and have kept Governments and health regulatory bodies on their toes. An amazing feature of the last two…
• Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board - BioSpace March 21, 2022 Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board  BioSpace
• The Bluerockers have started July 15, 2021 # # # # On the 8th June, BlueRock Therapeutics put out a press release announcing that the first participant in their Phase I clinical trial of cell transplantation for Parkinson’s had been dosed (Click here to read the press release). The initiation of this clinical trial by the company is a major step forward for them and for the…
• The luminance of a lighthouse January 24, 2022 # # # # LRRK2 inhibition represents one of several biological approaches to slowing the progression of Parkinson’s that is currently being clinically tested. Leading the charge in the development of LRRK2 inhibitors is a biotech company called Denali Therapeutics (in partnership with Biogen). Recently, the company provided news on the immediate future clinical development plans for their lead molecule…
• LumeNXT Names Marc Beer Chairman of the Board - P&T Community April 2, 2019 LumeNXT Names Marc Beer Chairman of the Board  P&T CommunityBOSTON, April 2, 2019 /PRNewswire/ -- LumeNXT, Inc. has appointed Marc Beer Chairman of the Board. LumeNXT is a privately-held company focused on the ...
• LumeNXT Names Marc Beer Chairman of the Board - PRNewswire April 2, 2019 LumeNXT Names Marc Beer Chairman of the Board  PRNewswireBOSTON, April 2, 2019 /PRNewswire/ -- LumeNXT, Inc. has appointed Marc Beer Chairman of the Board. LumeNXT is a privately-held company focused on the ...